Grace Halsey

Early forecasts of COVID-19 burden on US hospitals based on data from China may have underestimated need at peak infection, a new study suggests.

Diabetes patients are at risk for severe SARS-CoV2 infection. Here, find new evidence-based guidance from an international panel, on how to manage these patients.

Study authors project that, if COVID-19 returns, a 1-week delay in social distancing could require up to 17 more days to once again slow the spread.

FDA has asked 5 US companies to voluntarily recall lots of metformin extended release after detection of NDMA contamination.

The structural changes created in bariatric surgery increase the release of gut hormones that communicate satiety to the brain.

An independent association between asthma and risk of cardiovascular disease remained even after adjusting for other CVD risk factors, authors report.

Patients trust their doctors but are reluctant to visit any medical location, even for needed care, a new survey shows. More, here,on shifts in attitudes and behavior.

Hydroxychloroquine and chloroquine were associated with increased risk of death among more than 96 000 patients hospitalized with COVID-19.

US adults expect to see a COVID-19 vaccine this year and most (72%) are likely to get it. Here are demographics on this, vaccine clinical trials, and compassionate use.

The COVID-19 pandemic continues to be fertile ground for odd and often dangerous myths about transmission, prevention, and treatment. We found 5 new ones.

University of Oxford researchers will recruit more than 10 000 participants and evaluate groups of young and elderly to evaluate immune response across the lifespan.

As COVID-19 stay-at-home restrictions lift, primary care practices should be strategic about when and how to open. The AMA provides a step-by-step guide.

States with high concentrations of vulnerable populations, eg, older, sicker, but also poorer with basic needs unmet, face challenges as the COVID-19 lock-down lifts.

Analyses showed that times to first revascularization events were significantly reduced by icosapent ethyl vs placebo across subtypes of intervention.

The metabolic pathology that underlies obesity must be addressed through medication or bariatric surgery or significant weight loss will be transient.

A majority of group practices are seeing patients in person again as questions on safety, PPE supplies, and patient fears continue.

The most recent responses from primary care physicians to the hard questions about patients and practice (Survey May 6-12, 2020).

The orally administered antiviral agent will enter phase II trials to be conducted at multiple US locations, including 3 Mayo Clinic sites.

A blog post on COVID-19 transmission by a US biology professor at UMass Dartmouth went viral this week. Find out what your patients are reading and test yourself, too.

Antiviral remdesivir donated by Gilead Sciences is being shipped to areas in the US hardest hit by COVID-19.

The 2 new guidance documents provide sponsors with clear direction on data required for IND application and on the structure of phase 2 and 3 clinical trials.

Adherence to controller medication appears to have increased between early January and late March among patients with asthma and COPD, finds a new study.

NIH Tuesday released updates to its COVID-19 treatment guidelines including guidance on antithrombotic treatment and remdesivir clinical trial results.

Healthy white adipose tissue helps regulate endocrine activity that protects metabolic function. Dr Caroline Apovian explains how this function deteriorates as obesity progresses.

Poorly controlled blood glucose in patients with diabetes hospitalized for COVID-19 significantly reduces odds of survival.

A NIH clinical trial begins today that will compare antiviral remdesivir alone to remdesivir plus anti-inflammatory baricitinib in patients critically ill with COVID-19.

Americans are stocking up on prescriptions, wearing masks when they go out, are afraid for their mental health, and some will refuse a COVID-19 vaccine.

The SGLT-2 inhibitor is the first in its class to be approved for the treatment of adults with NYHA class II, III, or IV heart failure with reduced (≤40%) ejection fraction.

Anticoagulation was associated with increased survival time and bleeding events were similar between treated and non-treated patients.

More than half of primary care practices surveyed said less than 50% of visits during the previous week (in late April), were reimbursable. Nearly half rate the COVID-19 stress on their practice as severe.